TrialPhase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
Trial details
- Registry ID
- NCT06152042
- Phase
- Phase 2
BMEA
Biomea Fusion Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
5Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes MellitusNCT06152042 | BMEA | Phase 2 | Completed | 2025-05-20Actual |
| Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic TargetsNCT07502495 | BMEA | Phase 2 | Active not recruiting | 2027-03Estimated |
| Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based TherapyNCT07502508 | BMEA | Phase 2 | Recruiting | 2027-06Estimated |
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
Trial details
- Registry ID
- NCT07502495
- Phase
- Phase 2
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
Trial details
- Registry ID
- NCT07502508
- Phase
- Phase 2
Latest recorded trial changes
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
NCT06152042 · Biomea Fusion Inc.
Recruitment status changed
− Before
Terminated
+ After
Completed
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
NCT07502495 · Biomea Fusion Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
60 participants (planned)
+ After
64 participants (actual)
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
NCT07502495 · Biomea Fusion Inc.
Primary completion date changed
− Before
Jun 2027
+ After
Mar 2027